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This review focuses on the purinergic ionotropic receptor P2X7 (P2X7R) as a potential
target for developing drugs that delay the onset and/or disease progression in
patients with amyotrophic lateral sclerosis (ALS). Description of clinical and genetic
ALS features is followed by an analysis of advantages and drawbacks of transgenic
mouse models of disease based on mutations in a bunch of proteins, particularly
Cu/Zn superoxide dismutase (SOD1), TAR-DNA binding protein-43 (TDP-43), Fused in
Sarcoma/Translocated in Sarcoma (FUS), and Chromosome 9 open reading frame 72
(C9orf72). Though of limited value, these models are however critical to study the proof
of concept of new compounds, before reaching clinical trials. The authors also provide
a description of ALS pathogenesis including protein aggregation, calcium-dependent
excitotoxicity, dysfunction of calcium-binding proteins, ultrastructural mitochondrial
alterations, disruption of mitochondrial calcium handling, and overproduction of reactive
oxygen species (ROS). Understanding disease pathogenic pathways may ease the
identification of new drug targets. Subsequently, neuroinflammation linked with P2X7Rs
in ALS pathogenesis is described in order to understand the rationale of placing the use
of P2X7R antagonists as a new therapeutic pharmacological approach to ALS. This is
the basis for the hypothesis that a P2X7R blocker could mitigate the neuroinflammatory
state, indirectly leading to neuroprotection and higher motoneuron survival in
ALS patients.
Keywords: amyotrophic lateral sclerosis, ALS, neuroinflammation, P2X7, P2X7 receptor antagonists, calcium
dyshomeostasis, mitochondrial disruption, motoneuron death
Abbreviations: [Ca2+]c, Ca2+ concentration in the cytosol; ALS, amyotrophic lateral sclerosis; AMPA, α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid; BBB, blood–brain barrier; BBG, Brilliant Blue G; BDNF, brain-derived neurotrophic
factor; BzATP, 3’-O-(4-benzoyl)benzoyl-ATP; C9orf72, Chromosome 9 open reading frame 72; CBPs, calcium-binding
proteins; CNS, central nervous system; COX-2, cyclooxygenase-2; CSF, cerebrospinal fluid; CT, clinical trial; EAAT2,
excitatory amino acid transporter 2; fALS, familial ALS; FDA, U.S. Food and Drug Administration; FUS/TLS, Fused in
Sarcoma/Translocated in Sarcoma; GDNF, glia cell-derived neurotrophic factor; H2O2, hydrogen peroxide; HIV, human
immunodeficiency virus; ip, intraperitoneal; iv, intravenous; MCU, mitochondrial Ca2+ uniporter; mNCX, mitochondrial
Na+/Ca2+ exchanger; MN, motor neuron; NMDA, N-methyl-D-aspartate; NOX, NADPH oxidase; O2−, superoxide
radical; OXPHOS, mitochondrial oxidative phosphorylation system; P2X7R, purinergic P2X7 receptor; P90, postnatal day
90; PET, positron emission tomography; PK, pharmacokinetics; R, receptor; RAN, repeat-association non-ATG; ROS,
reactive oxygen species; sALS, sporadic ALS; SOD1, Cu/Zn superoxide dismutase; TAR, transactive response; TDP-43,
TAR-DNA binding protein-43; VACCs, voltage-activated calcium channels; VEGF, vascular endothelial growth factor;
WT, wild type.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive
neurodegenerative disease with upper and lower motor neuron
(MN) loss in the cerebral cortex, brainstem, and spinal cord.
Clinical symptoms start at 55 ± 15 years, with gradual loss
of daily motor activities, ambulation, speech and swallowing
impairment, compromised respiration, progressive paralysis,
and death within 3–5 years after diagnosis. Due to this prompt
death, disease prevalence is low; in the UK, the incidence is 1 in
472 women and 1 in 350 men (Alonso et al., 2009), while in the
USA, there are about 16,000 affected patients and 5,000 new
diagnosed cases every year (The ALS association, 2020).
For the last 25 years, the only pharmacological treatment
available has been riluzole, a drug that blocks glutamate
release from presynaptic terminals and accelerates glutamate
clearance from the synapse. Riluzole also elicits partial blockade
of presynaptic sodium channels and inhibits postsynaptic
N-methyl-D-aspartate (NMDA) receptors (Doble, 1996).
Unfortunately, riluzole is only able to prolong patients’ life for
approximately 2 months (Miller et al., 2003).
A second drug, edaravone, was approved by the U.S. Food
and Drug Administration (FDA) in 2017, with antioxidant
effects that presumably preserve MN viability (Cruz, 2018). This
approval generated great controversy inasmuch as it was based
in a single clinical trial (CT) performed in Japanese patients,
with genetic background distinct from that of Caucasian patients.
Furthermore, ALS incidence is lower in Asian population,
compared with European/American population (Chio et al.,
2013). In any case, it is worth mentioning that edaravone has
already been approved in Japan (2015), South Korea (2015), USA
(2017), Canada (2018), Switzerland (2019), and China (2019).
In light of the scarce therapeutic tools currently available
to delay the appearance of symptoms or disease progression,
we will analyze here the following aspects of ALS to be
able to extract meaningful conclusions for new drug therapy
approaches: (i) genetic features; (ii) mouse models of ALS,
based on gene mutations found in patients; (iii) pathogenic
signaling pathways involved in MN death, and potential drug
targets; (iv) neuroinflammation and the role of the purinergic
P2X7 receptor (P2X7R) in disease pathogenesis; (v) available
ligands for P2X7Rs; (vi) proof of concept of efficacy of some
P2X7R antagonists in mouse models of ALS; (vii) past and
ongoing CTs; and (viii) conclusions and perspectives.
GENETICS OF ALS
A family history is present in 5–10% of patients of ALS (familial
ALS or fALS). The first mutations reported were those in the
gene coding for Cu/Zn superoxide dismutase (SOD1) protein,
which account for around 15% of all fALS and 1–2% of the
sporadic cases (sporadic ALS or sALS) in European population
(Rosen et al., 1993; Stephenson and Amor, 2017; Zou et al., 2017).
Interestingly, these mutations (nearly 200 different mutations
have been reported) do not impair the enzymatic activity of
SOD1. Rather, they cause its pathological aggregation in the
cytosol or within mitochondria, leading to MN toxicity (Monk
and Shaw, 2006). The observation that all cell types express
SOD1, yet only MNs degenerate, is puzzling (Pasinelli and
Brown, 2006). This could be due to the low capacity of Ca2+
buffering exhibited by these neurons (Bezprozvanny, 2009; De
Diego et al., 2012).
Around 40 different mutations in the TARDBP gene, which
encodes for the transactive response (TAR)-DNA binding
protein-43 (TDP-43), have been described. Mutations account
for the 4–5% of fALS and <1% of sALS in European population
(Arai et al., 2006; Neumann et al., 2006; Zou et al., 2017).
These mutations cause the aggregation of TDP-43 protein in
the cell cytoplasm, which has important functions in RNA
processing and regulation. Interestingly, 97% of ALS patients
present TDP-43 inclusions that are only absent in patients
carrying SOD1 mutations, revealing the high relevance of this
protein in ALS pathogenesis.
Mutations in the Fused in Sarcoma/Translocated in Sarcoma
(FUS/TLS) gene have also been linked to the pathogenesis of ALS
(Lagier-Tourenne and Cleveland, 2009). Mutations in FUS are
present in 3% of fALS and <1% of sALS European patients (Zou
et al., 2017), and they are responsible for the early-onset forms of
the disease. This protein has relevant functions in RNA splicing
and transport, and it also forms aggregates in the cell cytoplasm
of ALS patients with this mutation.
Hexanucleotide repeats (GGGGCC) in intron 1 of
chromosome 9 open reading frame 72 (C9orf72) gene were
identified as the major cause of ALS, being present in 30–40% of
fALS and 5% of sALS cases in European population (DeJesus-
Hernandez et al., 2011; Renton et al., 2011; Majounie et al., 2012;
Zou et al., 2017). Hexanucleotide repeats seem to cause RNA
toxicity due to the expansion of sense and antisense RNAs, the
aggregation of RNA binding proteins, and the translation of
repeat-association non-ATG (RAN) proteins. Patients harboring
these mutations also present TDP-43 protein inclusions in the
cytoplasm (Liu Y. et al., 2016).
MODELING ALS GENETICS IN MICE
The ALS mutations mentioned above have been identified as
leading causes of disease, and based on them, several mouse
models have been developed. Ideally, mouse models should
present all the hallmarks of the human disease, namely, MN
loss, muscle weakness and atrophy, metabolic deficits, TDP-43
inclusions and proteinopathy, gliosis, and changes in innate
immunity. Even though available models are far from being
perfect, they have been useful to understand ALS pathogenesis,
to identify new drug targets with therapeutic potential, as well as
to establish the proof of concept of the efficacy and safety of lead
compounds (Stephenson and Amor, 2017). This is particularly
true for the SOD1G93A mice that is by far the model that has been,
and it is being used more frequently.
The discovery of new genes linked to ALS (Chia et al., 2018)
and the fast development of gene editing techniques such as
CRISPR/Cas9 will surely increase the number of ALS mouse
models, giving rise to a drug testing platform that includes
the high variability of the human disease. We describe below
the models that are more frequently used, emphasizing their
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advantages and caveats for drug discovery, previously described
in two detailed recent reviews (Stephenson and Amor, 2017;
Lutz, 2018).
SOD1 Models
SOD1 overexpressing mouse models were developed in the first
place, and they are still the most used when it comes to ALS
drug discovery (Rosen et al., 1993; Gurney et al., 1994). In
particular, the SOD1G93A mouse model has been the most used
and studied of all of them, as it closely resembles the disease
progression in humans. These mice develop a progressive MN
disease with adult onset and reduced lifespan. Pathogenically,
SOD1G93A mice show early onset astrogliosis and microgliosis,
glutamate-induced excitotoxicity, deficits in axonal transport,
axonal denervation, protein aggregation, aberrant neurofilament
processing, and mitochondrial vacuolization. All these processes
result in the selective loss of spinal cord MN and the marked
wasting, paralysis and atrophy of the forelimbs and hindlimbs.
Thus, this model exhibits almost all the hallmarks of ALS (Philips
and Rothstein, 2015; Lutz, 2018).
However, some disadvantages are found in this model. As
mutations in SOD1 are found in a minority of ALS cases, the
model is not representative of the whole patient population.
This is of great importance, as SOD1 mutations do not
result in TDP-43 inclusions in the SOD1G93A model, with this
hallmark of disease pathogenesis being not commonly present
in either SOD1 patients or mice (Stephenson and Amor, 2017).
However, other SOD1 models such as SOD1G86S do exhibit
TDP-43 inclusions and could be used to overcome this pitfall
(Jeon et al., 2019). Furthermore, while patients develop the
disease with basal quantities of the mutated protein, mice show
very high overexpression of the mutated SOD1 protein (Lutz,
2018). In addition, in mice, the disease always commences
in lumbar spinal cord MNs, while in humans, ALS onset
may be initiated in cortical, bulbar, or spinal cord MNs
(Philips and Rothstein, 2015).
TDP-43 Models
Mouse ALS models based in TARDBP mutations, encoding for
TDP-43 protein, have failed in most cases to mimic the human
disease, the overexpressing model TDP-43A315T being the best
one in resembling it. These mice show an adult onset, with
progressive and fatal neurodegeneration. Mice present TDP-43
aggregates, activation of astroglia and microglia, as well as MN
loss. However, survival is impaired by a severe gastrointestinal
pathology that can cause their sudden death previous to
neurodegeneration (Wegorzewska et al., 2009; Herdewyn et al.,
2014). Further limitations of the model are the overexpression of
mutated TDP-43 and a poor loss of spinal cord MNs.
FUS Models
The majority of mouse models based in human FUS mutations
do not present a complete ALS-like phenotype, neither
progression to paralysis or disease end stage. The model
that more closely resembles fALS is the wild type (WT)
overexpressing mouse or hFUSWT. Mice develop paralysis,
weight loss, muscle atrophy, and tremor. Moreover, MN loss,
protein aggregation, and gliosis are also present. The major
caveat of the model is that it does not carry a disease-linked
mutation and, hence, the underlying pathology may not be the
same as in the human disease (Mitchell et al., 2013).
C9orf72 Models
Again, most C9orf72-based models failed to develop an ALS-like
pathology. The most suitable model is the h(G4C2)37-500, which
shows muscle weakness, paralysis, weight loss, cognitive deficits,
and premature death. Moreover, mice show histopathological
hallmarks of the disease, such as MN loss, TDP-43 proteinopathy,
and gliosis. However, this pathology is only developed by a
30–35% of female subset of mice. Another 40% of females and
around 45% of males develop a milder pathology that in some
cases progresses to the disease end point (Liu Y. et al., 2016).
This heterogeneity seriously limits the use of this model to test
the effect of compounds within a drug development program.
ALS PATHOGENESIS
ALS pathogenesis is far from being completely understood.
Even though the disease is known to be multifactorial and
multisystem, it is still unknown why the selective death of MNs
occurs. Our limited knowledge on disease pathogenesis could
explain why over 50 CTs with a large variety of compounds
targeting different receptors and signaling pathways have
provided negative outcomes in ALS patients. We will review
here some features of disease pathogenesis such as cell Ca2+
dyshomeostasis, mitochondrial Ca2+ handling, and production
of reactive oxygen species (ROS). Neuroinflammation and
the role of P2X7 receptor (P2X7R) will be commented




The excitotoxic hypothesis implies that alterations of some of the
multiple receptors, ion channels, and calcium-binding proteins
(CBPs), could be the result of some of the ALS mutations
above described and the aggregation of pathological proteins
(Appel et al., 2001; Van Den Bosch et al., 2006; Bezprozvanny,
2009; Grosskreutz et al., 2010; De Diego et al., 2012). Several
factors support the assumption that augmented glutamatergic
neurotransmission and Ca2+-dependent excitotoxicity play
central relevant roles in MN degeneration (Patai et al., 2017).
They are as follows: (i) high levels of excitatory amino acids
have been found in the cerebrospinal fluid (CSF) of ALS patients
(Plaitakis and Caroscio, 1987; Rothstein et al., 1991; Fiszman
et al., 2010); (ii) CSF from ALS patients exerts MN death
in vitro (Terro et al., 1996; Sen et al., 2005; Anneser et al., 2006;
Gunasekaran et al., 2009; Yáñez et al., 2011); (iii) selective loss
of astroglial excitatory amino acid transporter 2 (EAAT2) in
motor cortex and spinal cord is found in both sporadic and fALS
(Rothstein et al., 1995; Fray et al., 1998; Lin et al., 1998; Sasaki
et al., 2000) with concomitant impairment of astrocytes’ ability
to remove glutamate from the synaptic cleft; (iv) a defective
glutamate clearance was detected in synaptosomes from brain
areas and spinal cord of sALS patients (Rothstein et al., 1992),
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but prolonged in vivo blockade of astroglial EAAT2 with
concomitant extracellular glutamate increase was innocuous
for spinal MNs in rats (Tovar et al., 2009); and (v) α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
(AMPARs) rather than NMDARs seem to contribute more to
MN cytotoxicity, firstly because they are expressed at higher
density in cultured MNs (Carriedo et al., 1996; Van Den
Bosch and Robberecht, 2000) and, secondly, because of their
higher Ca2+ permeability due to the lack of a GluR2 subunit
in the tetrameric receptor complex (Van Damme et al., 2002).
Consistent with this are the observations of lower GluR2 mRNA
levels in MNs compared with other neurons (Van Damme et al.,
2002), and the lower AMPAR mRNA in human spinal MNs
(Heath and Shaw, 2002). Furthermore, the lack of GluR2 in
SOD1G93A mice accelerated MN loss (Van Damme et al., 2005),
and conversely, GluR2 overexpression augmented MN lifespan
(Tateno et al., 2004). Of physiological and pharmacological
interest are the observations that the GluR2 subunit is regulated
by the vascular endothelial growth factor (VEGF; Bogaert et al.,
2010) as well as by the brain-derived neurotrophic factor (BDNF)
and glia cell-derived neurotrophic factor (GDNF; Brené et al.,
2000). Of note is the fact that these growth factors also contribute
to maintain MNs in good health. This is the case for VEGF
(Wang et al., 2016), BDNF (Lanuza et al., 2019), and GDNF
(Thomsen et al., 2018).
Strong or weak capacity to bind free Ca2+ ions in the
cytosol ([Ca2+]c) by CBPs has immediate consequences for
neuron vulnerability during Ca2+ loads in ALS-linked MN
degeneration. For instance, cortical, lower cranial, and spinal
MNs die soon after ALS onset, which correlates with their lack
of expression of the CBPs parvalbumin and calbindin-D28k.
In contrast, MNs from Onuf’s nucleus, oculomotor, trochlear,
and abducens nerves that express high levels of parvalbumin
and/or calbindin-D28k are resistant to damage or are injured
at advanced disease stages (Alexianu et al., 1994). Moreover,
in brain slices, the expression level of CBPs by different types
of neurons correlate with their specific vulnerability to Ca2+
loads (Ho et al., 1996; Beers et al., 2001; Van Den Bosch et al.,
2002). In line with these results, another experiment showed
that cross breeding SOD1 mutant mice with mice overexpressing
parvalbumin in spinal MNs resulted in a delay of disease onset
and a longer MN survival (Beers et al., 2001).
Altered Mitochondrial Calcium Handling
Mitochondria are involved in nearly all types of cell death,
including necrosis, apoptosis, and necroptosis (Kroemer
et al., 1998; Galluzzi and Kroemer, 2008). But notably, the
redistribution of mutated TDP-43 from the nucleus to the
cytoplasm is being considered a pathological hallmark for
most forms of ALS (Kabashi et al., 2008; Sreedharan et al.,
2008). A recent study demonstrates that TDP-43 toxicity
resides in its mitochondrial location. The aberrant protein
specifically impairs the Complex I of the mitochondrial
oxidative phosphorylation system (OXPHOS) by preferentially
binding to mitochondrial transcribed ND3/6 mRNAs as well
as by inhibiting their translation, leading to mitochondrial
dysfunction and neurodegeneration. The interest of this study
resides in the additional observation that the suppression of WT
or mutant TDP-43 in mitochondria restores neuronal viability.
This provides a rationale for reducing the aggregated TDP-43
protein inside the mitochondria as a therapeutic approach for
ALS (Wang et al., 2016).
Moreover, mitochondria in MNs from SOD1G93A and
TDP-43 mice show a swelling shape, have internal vacuoles
and disorganized cristae, and aggregate in abnormal clusters.
This causes a defect in mitochondrial axonal transport
towards the synaptic nerve terminals, leading to neuronal
metabolic alterations (Magrane et al., 2014). Mitochondria
also show aberrant fission and fusion dynamics that are
necessary for damaged mitochondria confinement and repair
(Smith et al., 2019).
The Link Between ROS and Mitochondrial
Calcium Cycling
ROS are natural metabolic products of cell functions and
particularly of oxidative phosphorylation itself. However,
impairment of mitochondrial electron transport chain generates
an excess of ROS that can damage cell proteins, membrane
lipids, and nucleic acids. In fact, several markers of ROS
damage, i.e., 3-nitrotyrosine, 8-hydroxy-2′-deoxyguanosine, and
4-hydroxynonenal, have been found in blood, CSF, and urine of
ALS patients, as well as in their spinal MNs (Smith et al., 1998;
Ihara et al., 2005; Mitsumoto et al., 2008).
Oxidative stress is also caused by a defect in the cellular
defense machinery against ROS. Such is the case of SOD1 that
catalyzes the conversion of superoxide radicals (O−2 ) into
hydrogen peroxide (H2O2). Physiological reduction of H2O2 into
oxygen and water through the action of glutathione and catalase
offers cell protection from ROS. Interestingly, the mutation of
SOD1 in ALS does not result in a loss of its enzymatic function,
but rather, it enhances its ability to oxidize cellular antioxidants,
reducing molecular oxygen to O−2 (Liochev and Fridovich, 2003).
Nevertheless, the MN toxicity linked to mutated SOD1 is mainly
due to the cytoplasmic aggregates created by the aberrant protein
(Hardiman et al., 2017).
Large Ca2+ loads occurring upon cell stimulation are cleared
up by mitochondria through the high-capacity mitochondrial
Ca2+ uniporter (MCU; Herrington et al., 1996; Xu et al.,
1997; Montero et al., 2000). The Ca2+ accumulated in the
mitochondrial matrix stimulates respiration and ATP synthesis,
to couple cell activity and bioenergetics needs (Gunter et al.,
1994; Rizzuto et al., 2000). During the excitotoxic process,
this accumulation could lead to excessive mitochondrial Ca2+
load, oxidative stress, and cell death (Cano-Abad et al., 2001;
Orrenius et al., 2003).
Correlation between Ca2+ influx with massive mitochondrial
Ca2+ uptake also occurs in hypoglossal MNs (Ladewig et al.,
2003). Such mitochondrial Ca2+ uptake is comparatively small
in highly Ca2+-buffered ALS-resistant spinal MNs (Carriedo
et al., 2000), suggesting that mitochondria could partially
compensate for the weak cytosolic Ca2+ buffering in vulnerable
neurons. In fact, following Ca2+ entry through voltage-activated
calcium channels (VACCs), substantial mitochondrial Ca2+
uptake occurs in weakly buffered neurons (Bergmann and Keller,
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2004). Mitochondria may exert an additional control of Ca2+
homeostasis through ROS-dependent regulation of excitability.
Thus, enhanced ROS production occurs upon inhibition of
respiration by sodium cyanide. ROS induces the opening of
sodium channels, augmentation of action potential firing and
enhanced voltage-dependent Ca2+ influx (Bergmann and Keller,
2004). Some studies support the idea that the production of
ROS is increased in spinal MN mitochondria as a result of Ca2+
overload following excitotoxic stimulation of AMPA/kainate
receptors (Carriedo et al., 2000).
Mitochondrial damage elicited by mutant SOD1 aggregates
found in the mitochondrial matrix of transgenic mice (Jaarsma
et al., 2001; Pasinelli et al., 2004) could decrease the enzymatic
activity of the electron transport chain at complexes I, II, and
IV (Jung et al., 2002; Mattiazzi et al., 2002). In fact, mutant
SOD1 could disrupt the association of complex IV (cytochrome
c) with the inner mitochondrial membrane, thereby interfering
with respiration (Kirkinezos et al., 2005). This leads to increased
ROS production as shown in mutant SOD1-expressing MNs
cultures (Kruman et al., 1999) as well as in MNs of brain
slices where complex IV was inhibited by sodium cyanide
(Bergmann and Keller, 2004).
It seems that ROS produced in MNs can diffuse to
neighboring astrocytes to cause oxidative disruption of glutamate
transporters (Rao et al., 2003). In turn, this will increase the
local extracellular concentration of glutamate, thereby enhancing
local excitotoxicity in a vicious circle of MN damage. This
model integrates the hypothesis of Ca2+-dependent excitotoxicity
and oxidative damage. In this frame, distorted mitochondrial
respiration sensitizes MNs to glutamate stimulation and
to environmental toxins, thus increasing their vulnerability
(Kruman et al., 1999; Andreassen et al., 2001). In this
direction, it was observed that in cultured neurons, the chronic
mitochondrial inhibition induced by malonate or sodium azide
led to selective MN death; free-radical scavengers and AMPAR
blockers protected such neurons from death (Kaal et al., 2000).
NEUROINFLAMMATION AND
P2X7 RECEPTORS IN ALS PATHOGENESIS
The purinergic P2X7 ionotropic receptor (P2X7R) is considered
as one of the main players of inflammation (Di Virgilio, 2015). In
fact, this receptor is expressed in immune and inflammatory cells
such as dendritic cells, osteoclasts, microglia, mast cells, natural
killer cells, or T and B lymphocytes. Additionally, P2X7Rs are
upregulated in inflammatory processes (Ferrari et al., 2006).
As a result of cell stress or tissue damage, large amounts
of ATP are released into the extracellular space that stimulates
the low-affinity target P2X7R, the main sensor for ATP during
inflammation. This receptor is also the main trigger of the
protective/regenerative immune response, consisting in the
maturation and release of several interleukins, mainly IL-1β
(Adinolfi et al., 2018).
The maturation of IL-1β requires the activation of
the NLRP3 inflammasome, an event that requires Na+
influx accompanied by water, Ca2+ influx, and K+ efflux.
The intracellular K+ drop is, in fact, the best established
mechanism underlying the P2X7R-mediated formation of the
NLRP3 inflammasome (Compan et al., 2012; Katsnelson et al.,
2015; Jo et al., 2016; Karmakar et al., 2016). This is supported
by experiments showing that not only ATP, but also other
agents that induce K+ efflux, such as the ionophore nigericin
or crystalline molecules, elicit inflammasome activation too
(Compan et al., 2012; Yaron et al., 2015). Noteworthy, ROS,
also, induce inflammasome aggregation and IL-1β release due to
P2X7R activation (Hung et al., 2013; Minkiewicz et al., 2013).
The role of P2X7Rs in neuroinflammation is supported
by the fact that they are expressed in various cells of the
central nervous system (CNS), namely, astrocytes, microglia,
and oligodendrocytes (Sperlagh et al., 2006; Kaczmarek-Hajek
et al., 2018), where they mediate inflammasome signaling
(Franceschini et al., 2015). The presence of reactive astrocytes
and microglia define the neuroinflammatory process in the CNS.
As peripheral immune and endothelial cells, activated microglia
and astrocytes produce pro-inflammatory cytokines (IL-1β,
IL-16, TNF-α), chemokines (CCL2, CCL9, CCL1), ROS, and
secondary messengers (nitric oxide, prostaglandins; DiSabato
et al., 2016). However, the activation of P2X7Rs in these cells
is known to produce dual and divergent effects depending on
the duration of the inflammatory stimulus and the disease stage,
presymptomatic or symptomatic.
How neuroinflammation contributes to neurodegeneration
has recently been analyzed by Ransohoff (2016). Thus, a chronic
mild activation of glial cells via P2X7Rs leads, in the long term,
to synaptic dysfunction, synapse loss, and neuronal death. The
fact that glial cells exhibit a low overall turnover rate make them
more susceptible to the neuroinflammatory effects of age, injury,
or stress in neurodegenerative diseases (Ajami et al., 2007).
A dual effect of P2X7R-mediated neuroinflammation seems
to operate during the time course of ALS. This could be
explained in the context of two different phenotypes that
microglia develop upon P2X7R activation. The M2 phenotype
or anti-inflammatory predominates at earlier disease stages,
while the pro-inflammatory M1 phenotype is prevalent at later
disease stages in SOD1G93A mice (Liao et al., 2012; Parisi et al.,
2016). Consistent with this is an experiment done in SOD1G93A
mice with genetic ablation of P2X7Rs; exacerbation of gliosis
and enhanced MN death were unexpectedly found in these
mice (Apolloni et al., 2013a). Another experiment supporting
duality indicated that short P2X7R stimulation augmented
autophagy and M2 microglial markers. However, continued
P2X7R stimulation impaired autophagy, suggesting a microglial
shift to the M1 phenotype. A dual report that implies duality of
action at central and peripheral tissues indicated a positive role
of P2X7Rs on SOD1G93A muscles (Fabbrizio et al., 2020).
A few preclinical and clinical experiments support
the implication of P2X7Rs in ALS pathogenesis. So, the
pro-inflammatory action of microglial P2X7Rs was augmented
in SOD1G93A mice (D’Ambrosi et al., 2009). Furthermore, spinal
cord pathology was ameliorated by P2X7R antagonism, also in
these mice (Apolloni et al., 2014). Consistent with this was the
observation that P2X7R activation by high ATP concentrations
activated NOX2 and the kinase ERK1/2 in the microglia of
SOD1G93A mice, thus provoking an increase of ROS (Apolloni
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et al., 2013b). Additionally, in co-cultures of astrocytes and MNs
from SOD1G93A mice, cell stimulation with P2X7R agonists ATP
and 3′-O-(4-Benzoyl)benzoyl ATP (BzATP) elicited a neurotoxic
phenotype that was prevented by the P2X7R blocker Brilliant
Blue G (BBG; Gandelman et al., 2010). However, unexpected
P2X7R down-regulation and Ca2+ dyshomeostasis was found in
peripheral monocytes of ALS patients (Liu J. et al., 2016). This
contrasts with another study showing up-regulation in spinal
cord tissue of post-mortem ALS patients (Yiangou et al., 2006).
This cumulative set of data mostly from preclinical in vitro
and in vivo models of ALS, plus a scarce number of clinical
studies in ALS patients, support the view in the sense that
P2X7Rs mediate the activation of astrocytes and microglia, giving
rise to a chronic neuroinflammatory state that is critical in
the progression of ALS pathology. However, it should be kept
in mind that dependent on disease stage, microglial activation
may be anti-inflammatory (early stage, M2 phenotype) or
pro-inflammatory (late stage, M1 phenotype).
SOME P2X7R BLOCKERS WITH
FAVORABLE PHARMACOKINETICS
Due to its involvement in neuroinflammation, the P2X7R is
considered an adequate target for the treatment of several
neurodegenerative and neurological diseases, as well as mood
disorders (Díaz-Hernández et al., 2009; Hempel et al., 2013;
Bhattacharya and Biber, 2016; Jimenez-Pacheco et al., 2016;
Volonte et al., 2016; Cieslak and Wojtczak, 2018; Cieslak et al.,
2019). Yet, preclinical data in mouse models of ALS leave
some uncertainty about it, as previously described. Moreover,
P2X7R antagonists have not succeeded in any CT for CNS
disorders so far (ClinicalTrials.gov - NIH U.S. National Library
of Medicine, 2020). Despite the notable number of P2X7R
blockers already existing as pharmacological tools, not all meet
the pharmacokinetic (PK) characteristics that are necessary to
become a potential drug for the treatment of neurodegenerative
diseases, including ALS. This is the case of BBG that has
been amply used as a P2X7R blocker only because it is cheap
and readily available. However, this compound has a poor
selectivity towards P2X7Rs, blocking also P2X4, P2X5, and
rat P2Y1 and P2Y2, while potentiating the human P2Y1 at
1–3 µM concentrations (Jacobson et al., 2002, 2006; Jacobson,
2010). Research has led nowadays to very potent antagonists,
but unfortunately, this is not enough. Between the main
problems of these compounds, there is a lack of favorable PK
properties, such as low blood–brain barrier (BBB) permeability
and scarce stability in blood and brain tissue, which determine
a drop in drug half-life and CNS residence time. Additionally,
pronounced differences have been found in potencies and
affinities among P2X7R in mouse, rat, and human. Such is the
case of AZ11645373 (Figure 1) that blocks the human P2X7R at
nanomolar concentrations and the mouse P2X7R at micromolar
concentrations and has no effect on the rat orthologous (Michel
et al., 2009). Another example is compound GW791343, which
is a potent allosteric inhibitor of the human receptor, but also
a positive allosteric modulator of rat P2X7R (Jacobson, 2010).
This complicates the scenario for the development of a drug for
FIGURE 1 | P2X7R antagonists lacking adequate pharmacokinetic
properties for the treatment of CNS disorders.
clinical use and diminishes the possibility for a new compound
of being selected for preclinical and clinical studies.
During around the last 10–15 years, the interest in finding new
P2X7R clinical candidates has shifted from no-BBB-permeable
antagonists for the treatment of peripheral inflammatory diseases
(e.g., AZD-9056 from AstraZeneca, tried in CTs—Figure 1) to
BBB-permeable blockers, mainly due to the increasing awareness
of P2X7R role in CNS disorders (Bhattacharya and Biber, 2016;
Bhattacharya, 2018).
However, just increasing lipophilicity is not always highly
recommended for the development of BBB-permeable drugs.
In fact, this can penalize other important PK properties like
solubility, enzyme metabolism, blood protein binding, and
half-life. After the development of the high lipophilic o-
chlorobenzamide P2X7R antagonists by Pfizer, their attempts
were focused on the increase of molecular polarity, giving a good
clinical candidate that, however, was no longer CNS penetrant
(CE-244,535—Figure 1; Duplantier et al., 2011).
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Abbott Laboratories developed several potent P2X7R
antagonists, mainly tetrazoles and cyanoguanidines. Thus,
tetrazole derivative A-438079 (Figure 1) was very appealing
for its small molecular weight, good potency, and efficacy in
reverting allodynia in the Chung model of neuropathic pain.
Nevertheless, its half-life of 1 h and low bioavailability after
intraperitoneal (ip) administration was discouraging (Guile
et al., 2009). Cyanoguanidine A-740003 (Figure 1) was found
to have a better half-life after iv administration (t 1
2
= 4 h) but
not a good BBB permeability, as confirmed by its radiotracer
[11C]A-740003 (Janssen et al., 2014). Cyanoguanidine A-804598
(Figure 2) has the best balance of pharmacodynamics and
PK properties. In fact, it is potent (IC50 of around 10 nM for
mouse, rat, and human species, vs. the potency of A-740003
ranging from 44 to 150 nM in the different orthologs), selective
for the P2X7R, and brain-permeable, persisting in brain
tissues at least for 1 h after administration, as shown in ex
vivo studies of receptor occupancy (Able et al., 2011). More
recently, Abbott has developed new potent P2X7R antagonists
by adding the adamantine core to cyanoguanidines (compound
1—Figure 1), but without great PK improvements (e.g.,
t 1
2
= 0.22 h; O’Brien-Brown et al., 2017).
GlaxoSmithKline developed a series of compounds
with excellent physicochemical properties, such as the
BBB-permeable GSK-1482160 in rats (Figure 1; Abdi et al.,
2010). Unfortunately, deeper studies on its metabolism
pathway explained why some parameters, like its half-life,
worsened in dog and monkey models, blocking its clinical
development. Anyway, new chemical modifications succeeded
in overcoming this problem. Among the compounds of this
new series, the oxoimidazolidine 2 (Figure 2) stands out
(Abberley et al., 2010).
It is a fact that Janssen Pharmaceuticals has probably
developed the most interesting P2X7R antagonists as clinical
FIGURE 2 | P2X7R antagonists with optimal pharmacokinetic properties for
the treatment of CNS disorders.
candidates for the treatment of CNS diseases. One of the
most used ligands in basic and preclinical research is JNJ-
47965567 (Figure 1). Unfortunately, its poor oral bioavailability,
as well as the lack of deeper details on its residence time
in brain, stopped its clinical progress (Bhattacharya et al.,
2013). However, new series of dihydro- and tetrahydro-
triazolopyridines were discovered and extensively optimized.
Among these, JNJ-54175446 and JNJ-55308942 (Figure 2)
have optimal PK properties like solubility, metabolism
profile, bioavailability, and half-life, as well as good BBB
permeability and tolerability (Letavic et al., 2017; Chrovian
et al., 2018). Proof of this is the fact that they were chosen as
clinical candidates and that JNJ-55308942 has completed
three phase I CTs, while JNJ-54175446 is currently in
a phase II CT for major depression (ClinicalTrials.gov
- NIH U.S. National Library of Medicine, 2020;
Recourt et al., 2020).
PROOF OF CONCEPT OF P2X7Rs AS A
DRUGGABLE TARGET IN ALS
The proof of concept that a P2X7R antagonist could have
promising therapeutic potential in ALS has been tested in the
SOD1G93A mouse model of ALS (Table 1). In a first study, BBG
was administered intraperitoneally at a dose of 45.5 mg/kg every
48 h, starting at postnatal day 90 (P90), a late pre-onset disease
stage. The treatment improved deficits in motor performance to
a greater extent in males than in females, but no effect on survival
was observed (Cervetto et al., 2013).
Taking into account the dual role of P2X7Rs (protection at
early stages and promotion of cell death at advanced disease
stages), an experiment was designed changing the dose and
defining different start points of BBG administration (250 mg/kg,
3 times/week). Starting at late pre-onset stage (P100), higher
MN survival and reduced microgliosis were observed in the
spinal cord of SODG93A mice. Moreover, disease onset was
delayed and motor performance was improved in both males
and females, although survival was not affected. This was not
the case when BBG was administered at pre-symptomatic stages,
supporting the hypothesis of the dual role of P2X7R in ALS
(Apolloni et al., 2014).
In a third experiment, BBG administration at pre-onset
stage or P62–P64 (45.5 mg/kg, three times/week) reduced body
weight loss in females but not in males, a sign of delayed
muscle loss. Survival was also augmented in females but not
in males, and motor performance was unaffected in either sex
(Bartlett et al., 2017).
Finally, two experiments have used more potent and
specific P2X7R antagonists. When the antagonist A-804598
was administered to female mice five times/week at 30 mg/kg,
no effects on motor performance, disease onset, or survival
were observed (Fabbrizio et al., 2017). Same negative results
were obtained with the administration of the antagonist
JNJ-47965567 from P100, three times/week at 30 mg/kg
(Ly et al., 2020).
These erratic, yet mild positive outcomes suggest that
the experimental conditions of future experiments should
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TABLE 1 | Proof of concept of P2X7R antagonism on clinical outcomes in SOD1G93A mice.
Reference Treatment Treatment starting point Main outcomes
Cervetto et al. (2013) BBG, 45.5 mg/kg, every 48 h, ip P90 (pre-onset) to humane end point • Improvement in motor performance in both
genders, although greater effect in males.
• Delayed weight loss in males.
• No difference in survival was observed.
Apolloni et al. (2014) BBG, 50 mg/kg, three times/week, ip P100 (late pre-onset) and P135 (onset)
to humane end point
• Improvement in motor performance in mice
treated from onset.
• Disease onset and survival not affected.
BBG, 250 mg/kg, three times/week, ip P40 (asymptomatic), P70 (pre-onset),
P100 (late pre-onset) to humane end
point
• Improved behavioral scores and motor
performance in mice treated from late
pre-onset.
• No differences in survival.
• Decrease in microgliosis, inflammatory
markers and motor neuron loss in late
pre-onset treated animals.
Bartlett et al. (2017) BBG, 45.5 mg/kg, three times/week, ip P60 (pre-onset) to humane end point • Reduced body weight loss and prolonged
survival in females.
• No effect on clinical score or motor
performance
Fabbrizio et al. (2017) A-804598, 30 mg/kg, five times/week,
ip
P100 (pre-onset) to humane end point • No effect on motor performance, behavioral
scores or survival observed
Ly et al. (2020) JNJ-47965567, 30 mg/kg, three
times/week, ip
P100 (onset) to humane end point • No effect on motor performance, ALS score
or survival observed.
• No altered gene expression in spinal cord.
• No altered proportions of lymphoid
leukocytes.
• No effect on serum cytokines.
be considered as follows: (i) to adjust drug administration
starting point; (ii) to define better the dosing and frequency
of administration, according to (iii) the PK drug properties,
including the BBB permeability and CNS residence
time, longer half-life and solubility; and (iv) to include
both females and males and, if possible, different ALS
mouse models.
FROM BENCH TO CLINICAL TRIALS
Recent reviews (Petrov et al., 2017; Andrews et al., 2019;
Chipika et al., 2019) analyze the outcomes of over 50 CTs
performed in ALS patients, since riluzole was available.
Various druggable potential targets have been addressed:
(1) antiglutamatergic compounds (riluzole, memantine,
talampanel, ceftriaxone); (2) antioxidant agents (edaravone,
coenzyme Q, creatine); (3) anti-inflammatory drugs (valproic
acid, NP001, glatiramer acetate, minocycline, pioglitazone,
erythropoietin, celecoxib); (4) neurotrophic factors (IGF-1,
CNTF, BDNF); (5) lithium; (6) inhibitors of kinase (masitinib,
fasudil); and (7) neuroprotective compounds (xaliproden,
dexpramipexole, olesoxime, omigapil).
Despite riluzole and edaravone being approved by the FDA
after having been tested in CTs, they gave poor clinical outcomes.
In the case of riluzole, two out of three late-stage CTs reported
negative outcomes. Similarly, in the case of edaravone, two
out of three phase III CTs also reported negative results. The
rest of the compounds and drugs tested provided negative
results in CTs.
Masitinib is emerging as a singular agent to mitigate
microgliosis and neuroinflammation. The compound also
prolongs survival when administered to SOD1G93A ALS mice
at the onset of paralysis (Trias et al., 2016). An add-on
riluzole therapy phase III CT reported significant outcomes in
ALS patients treated with masitinib [Masitinib in Combination
With Riluzole for the Treatment of Patients Suffering From
Amyotrophic Lateral Sclerosis (ALS), 2018].
CONCLUSIONS AND PERSPECTIVES
Much is known about clinical features and pathogenic pathways
of ALS. Cumulating knowledge, derived from in vitro and
in vivo disease models, as well as from patients and postmortem
tissues, outlines the sequence of the pathophysiological events
involved in ALS. These could be hypothetically ordered as
follows: (1) cytosolic and mitochondrial protein aggregation,
affecting mitochondrial ultrastructure and function; (2) distorted
mitochondrial calcium handling and circulation; (3) deficits in
ATP generation and excess of ROS production; (4) reactive
microglia and production of inflammatory mediators; and
(5) enhanced MN vulnerability and death.
Regarding disease pathogenesis, a crucial open question
remains: are the pathogenic features common for both sporadic
and familial ALS? And also, why do only MNs die, if mutated
proteins are expressed in all cell types? Given the complexity
of ALS pathogenesis, why have CTs been performed using
single-target compounds in the last 20 years? In light of
the chronic inflammatory background, should we target with
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neuroprotective agents only the MNs, or the activated glia, or
both? Much further research is required before we can answer
these questions.
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